Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(7%)

Phase Distribution

Ph not_applicable
2
14%
Ph phase_2
5
36%
Ph phase_3
1
7%
Ph phase_4
4
29%
Ph early_phase_1
1
7%

Phase Distribution

1

Early Stage

5

Mid Stage

5

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 2Efficacy & side effects
5(38.5%)
Phase 3Large-scale testing
1(7.7%)
Phase 4Post-market surveillance
4(30.8%)
N/ANon-phased studies
2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

70.0%

7 of 10 finished

Non-Completion Rate

30.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(7)
Terminated(3)
Other(4)

Detailed Status

Completed7
unknown3
Withdrawn2
Suspended1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (7.7%)
Phase 25 (38.5%)
Phase 31 (7.7%)
Phase 44 (30.8%)
N/A2 (15.4%)

Trials by Status

suspended17%
unknown321%
completed750%
terminated17%
withdrawn214%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT04887467Phase 4

Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease

Completed
NCT02940912Phase 4

Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease

Completed
NCT03693872Not Applicable

Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals

Completed
NCT02864004Phase 3

Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)

Unknown
NCT04786158

Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)

Completed
NCT00472355Phase 2

Low Dose Apomorphine and Parkinsonism

Withdrawn
NCT00758368Phase 2

Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease

Withdrawn
NCT02688465Phase 4

Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).

Terminated
NCT02702076Phase 2

Apomorphine in Parkinson's Disease Patients With Visual Hallucinations

Unknown
NCT00761228Phase 2

Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury

Suspended
NCT02969629Phase 4

The Effects of Apomorphine on Experimental and Clinical Pain in Patients With Chronic Radicular Pain

Completed
NCT01744964Early Phase 1

Apomorphine Effects on Experimental Pain

Completed
NCT00437177Phase 2

Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)

Unknown
NCT00524914Not Applicable

Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14